NO20051265L - Anvendelse av og noen nye imidazopyridiner - Google Patents

Anvendelse av og noen nye imidazopyridiner

Info

Publication number
NO20051265L
NO20051265L NO20051265A NO20051265A NO20051265L NO 20051265 L NO20051265 L NO 20051265L NO 20051265 A NO20051265 A NO 20051265A NO 20051265 A NO20051265 A NO 20051265A NO 20051265 L NO20051265 L NO 20051265L
Authority
NO
Norway
Prior art keywords
sup
formula
disclosed
imidazopyridines
new
Prior art date
Application number
NO20051265A
Other languages
English (en)
Inventor
Peter Sjo
Peter Storm
Karolina Lawitz
Grigorios Nikitidis
Henrik Johansson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20051265L publication Critical patent/NO20051265L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Anvendelse av en forbindelse med formel (I) ..IB V-Ar¿(R': (0 hvori r', R^, r"*, m og Ar er som definert i lieskrivelsen og farmasøytisk akseptable salter derav for fremstilling av medikament for behandling eller profylakse av sykdommer eller tilstander hvori inhibering av kinase Itk-aktivitet er fordelaktig er beskrevet. Visse nye forbindelser med formel (I) sammen med fremgangsmåter for fremstilling, sammensetninger som inneholder dem og deres anvendelse ved behandling er også beskrevet.
NO20051265A 2002-08-14 2005-03-11 Anvendelse av og noen nye imidazopyridiner NO20051265L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202462A SE0202462D0 (sv) 2002-08-14 2002-08-14 Novel use
PCT/SE2003/001279 WO2004016611A1 (en) 2002-08-14 2003-08-13 Use of and some novel imidazopyridines

Publications (1)

Publication Number Publication Date
NO20051265L true NO20051265L (no) 2005-05-12

Family

ID=20288750

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051265A NO20051265L (no) 2002-08-14 2005-03-11 Anvendelse av og noen nye imidazopyridiner

Country Status (18)

Country Link
US (1) US7410966B2 (no)
EP (1) EP1539759B1 (no)
JP (1) JP2006503010A (no)
KR (1) KR20060005333A (no)
CN (1) CN100358893C (no)
AT (1) ATE370138T1 (no)
AU (1) AU2003251272A1 (no)
BR (1) BR0313461A (no)
CA (1) CA2495511A1 (no)
DE (1) DE60315674T2 (no)
ES (1) ES2290538T3 (no)
IL (1) IL166413A0 (no)
MX (1) MXPA05001581A (no)
NO (1) NO20051265L (no)
NZ (1) NZ538156A (no)
SE (1) SE0202462D0 (no)
WO (1) WO2004016611A1 (no)
ZA (1) ZA200500887B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550087A (en) 2004-03-25 2009-06-26 Janssen Pharmaceutica Nv Imidazole compounds
BRPI0512239A (pt) 2004-06-17 2008-02-19 Wyeth Corp processos para preparação de antagonistas de receptores de hormÈnios liberadores de gonatropina
RU2007101544A (ru) 2004-06-17 2008-08-10 Уайт (Us) Антагонисты рецепторов высвобождающего гонадотропин гормона
US7799778B1 (en) * 2005-01-12 2010-09-21 Alcon, Inc. 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
JP5071374B2 (ja) * 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
CN101208339B (zh) 2005-08-01 2010-12-29 霍夫曼-拉罗奇有限公司 杂环苄基氨基衍生物，它们的制备以及作为药剂的应用
BRPI0503681A (pt) 2005-08-19 2007-04-10 Fundacao Oswaldo Cruz compostos azóis usados como agentes tuberculostáticos e leishmanicidas, composições farmacêuticas contendo os mesmos, uso das respectivas composições farmacêuticas no tratamento ou inibição de doenças, bem como método de tratamento ou inibição de doenças
UY29823A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
EP1954287B2 (en) † 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
EP1963315B1 (en) * 2005-12-22 2014-10-08 Cancer Research Technology Limited Enzyme inhibitors
CA2637392A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
ITMI20061581A1 (it) * 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP2366703B1 (en) * 2007-02-13 2014-07-30 AB Science Polymorph form of 2-amino (nitroaryl) thiazole derivative
WO2008121064A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
MX2009010165A (es) * 2007-03-30 2009-10-12 Astrazeneca Ab Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
WO2009001021A1 (en) * 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
TWI385174B (zh) * 2008-11-10 2013-02-11 Nat Health Research Institutes 作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
NZ608685A (en) * 2010-09-28 2014-10-31 Dae Woong Pharma Novel method of preparing benzoimidazole derivatives
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103724331A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
TWI620565B (zh) 2013-10-25 2018-04-11 製藥公司 治療及預防移植物抗宿主病之方法
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
EP3189048B1 (en) 2014-09-03 2021-03-17 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
BR112017016428B1 (pt) 2015-02-02 2023-10-24 Kancera Ab Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável
EP3344254A1 (en) 2015-08-31 2018-07-11 Pharmacyclics LLC Btk inhibitor combinations for treating multiple myeloma
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
US11008318B2 (en) 2016-07-11 2021-05-18 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
CA3042049A1 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
MX2020011527A (es) 2018-05-03 2021-02-26 Juno Therapeutics Inc Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
BR112022016400A2 (pt) 2020-02-18 2022-10-25 Bayer Ag Compostos inovadores de heteroaril-triazol como pesticidas
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985891A (en) * 1973-02-03 1976-10-12 Boehringer Ingelheim Gmbh 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof
DE3037464A1 (de) 1980-10-03 1982-05-19 Dr. Karl Thomae Gmbh, 7950 Biberach 6-hydroxy-2-phenyl-imidazo 4,5-b zu pyridine, ihre herstellung und diese sie enthaltende arzneimittel
US5296591A (en) * 1990-12-31 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Trifluoromethylketone derivatives, processes for preparation thereof and use thereof
MXPA02010763A (es) * 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
WO2002048152A2 (en) * 2000-12-12 2002-06-20 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines

Also Published As

Publication number Publication date
MXPA05001581A (es) 2005-04-25
IL166413A0 (en) 2006-01-15
DE60315674D1 (de) 2007-09-27
NZ538156A (en) 2006-09-29
KR20060005333A (ko) 2006-01-17
CN1684964A (zh) 2005-10-19
JP2006503010A (ja) 2006-01-26
CN100358893C (zh) 2008-01-02
ZA200500887B (en) 2006-02-22
ES2290538T3 (es) 2008-02-16
AU2003251272A1 (en) 2004-03-03
SE0202462D0 (sv) 2002-08-14
US20050261333A1 (en) 2005-11-24
ATE370138T1 (de) 2007-09-15
BR0313461A (pt) 2005-07-05
US7410966B2 (en) 2008-08-12
EP1539759A1 (en) 2005-06-15
DE60315674T2 (de) 2008-06-19
EP1539759B1 (en) 2007-08-15
WO2004016611A1 (en) 2004-02-26
CA2495511A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
NO20051265L (no) Anvendelse av og noen nye imidazopyridiner
IL166412A0 (en) Novel use of benzothiazole derivatives
IL150635A0 (en) Novel use of phenylheteroalkylamine derivatives
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
SE0202463D0 (sv) Novel compounds
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
GB0112348D0 (en) Compounds
NO331002B1 (no) Tioxantinderivater og farmasoytiske preparater med tioxantinderivater
MY133527A (en) Isoquinoline derivatives
IL150640A0 (en) Novel use of phenylheteroalkylamine derivatives
NO20045353L (no) Orto-substituerte benzosyrederivater for behandling av insulinresistens
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
ATE441653T1 (de) Phosphorenthaltende verbindugnen mit antithrombitische wirkung
NO20061077L (no) Nye farnesyl-protein-transferaseinbibitorer som antitumormidler
SE9901530D0 (sv) Novel compounds
SE0201193D0 (sv) Novel use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application